|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-7-22
|
|
pubmed:abstractText |
Estramustine phosphate (EMP) in combination with other cytotoxic agents has been widely used in clinical trials as an anti-tumor agent for the treatment of hormone-refractory prostate cancer (HRPC). However, few prospective studies have considered the efficacy of EMP monotherapy for HRPC patients following androgen-deprivation therapy (ADT), given the availability of methods to measure prostate-specific antigen (PSA) levels in the serum. We therefore initiated a prospective study to determine whether EMP is efficient for HRPC following ADT using changes in PSA levels as the major endpoint.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0042-1138
|
|
pubmed:author |
pubmed-author:EndohMakotoM,
pubmed-author:HachiyaTakahikoT,
pubmed-author:HiranoDaisakuD,
pubmed-author:IshidaHajimeH,
pubmed-author:KishimotoYuichiY,
pubmed-author:MineiSadatsuguS,
pubmed-author:OkadaKiyokiK,
pubmed-author:SatohYasuoY,
pubmed-author:TakimotoYukieY,
pubmed-author:YamaguchiKenyaK,
pubmed-author:YamamotoTadaoT,
pubmed-author:YamanakaYatarohY,
pubmed-author:YoshidaToshioT,
pubmed-author:YoshikawaTetsuoT
|
|
pubmed:copyrightInfo |
2005 S. Karger AG, Basel
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
75
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
43-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16037707-Adenocarcinoma,
pubmed-meshheading:16037707-Aged,
pubmed-meshheading:16037707-Aged, 80 and over,
pubmed-meshheading:16037707-Androgens,
pubmed-meshheading:16037707-Antineoplastic Agents, Hormonal,
pubmed-meshheading:16037707-Disease Progression,
pubmed-meshheading:16037707-Estramustine,
pubmed-meshheading:16037707-Follow-Up Studies,
pubmed-meshheading:16037707-Humans,
pubmed-meshheading:16037707-Male,
pubmed-meshheading:16037707-Middle Aged,
pubmed-meshheading:16037707-Neoplasm Staging,
pubmed-meshheading:16037707-Prospective Studies,
pubmed-meshheading:16037707-Prostate-Specific Antigen,
pubmed-meshheading:16037707-Prostatic Neoplasms,
pubmed-meshheading:16037707-Treatment Outcome,
pubmed-meshheading:16037707-Tumor Markers, Biological
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
|
|
pubmed:affiliation |
Department of Urology, Nihon University School of Medicine, Tokyo, Japan. byd04561@nifty.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Multicenter Study
|
